Developing GA101, A Humanized Anti-CD20 Monoclonal Antibody With Hematological Malignancies Potential Treatment - Genentech, GlycArt And Roche Collabo Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.
Source: www.medicalnewstoday.com
# posted by Network @ 12:30 PM
